Mosedipimod

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameMosedipimod
Drug Alias NameEC-18
ClassificationSmall molecules
Mechanisms of ActionToll like receptor 4 inhibitors
TargetsToll like receptor 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Dermatitis, AtopicFebrile Neutropenia +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEnzychem Lifesciences Co
China Registration ClassN/A

Develop Information

Active CompaniesEnzychem Lifesciences Co
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Febrile NeutropeniaNeutropenia +[4

Other Information

ATC CodeN/A
Related LinksN/A